Company research
CIK 2124080Updated Nov 10, 2026
Loading TradingView…
NASDAQ:ASPE on TradingView ↗We are developing sasineprocel, a single-dose, autologous iPSC-based therapeutic candidate for PD that is designed to replace a patient’s lost dopamine neurons. We are currently conducting the open-label Phase 1/2a ASPIRO trial of a single dose of sasineprocel in mid-stage to moderately advanced PD patients. The trial consists of four cohorts at two dose levels, both of which were anticipated to be biologically active and have pharmacologic effects based on our preclinical modeling, with sasineprocel administered as a single bilateral intracranial injection into the post-commissural putamen using well-understood, standard stereotactic neurosurgical techniques.
No coverage from other publishers is available.
Underwriters: Leerink Partners LLC, Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated, UBS Securities LLC, Oppenheimer & Co. Inc.
Exhibit 1 AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of Aspen Neuroscience, Inc. This Agreement may be executed in any number of counterparts, each of which shall be deemed an original. Dated: November 9, 2026 ARCH VENTURE FUND X, L.P. By: ARCH Venture Partner…
Read attachment ↗Exhibit 4.1 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (as amended from time to time, this “Agreement”), is made as of the 1st day of October, 2025, by and among Aspen Neuroscience, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, and each of the stockholders listed on Schedule B hereto, each of whom is referred to here…
Read attachment ↗